ArticleFrontiers in neurology
Inflammatory biomarker panels in peripheral blood: association with myasthenia gravis onset and severity.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the association between peripheral blood inflammatory biomarkers and the clinical phenotypes, severity, and prognosis of myasthenia gravis (MG). Methods: This retrospective study analyzed 134 MG patients (including 23 with myasthenic crisis [MC]) and 58 age- and sex-matched healthy controls hospitalized at the Second Affiliated Hospital of Soochow University (August 2016-March 2024). Peripheral blood inflammatory markers were compared across subgroups. Infection was strictly excluded based on clinical and laboratory criteria. Multivariate logistic regression and receiver operating characteristic (ROC) curve analyses were performed to identify risk factors and diagnostic value. Results: Compared to controls, MG patients exhibited significantly elevated neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI) (all Conclusion: Systemic inflammatory biomarkers, particularly PLR and NLR, are significantly elevated in MG and correlate with disease severity and clinical subtypes. While PLR is associated with MG onset, NLR and thymoma are potential indicators for myasthenic crisis. These readily available markers may facilitate risk stratification in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.